Pancreatic Cancer

We combine evidence-based medicine with compassionate, personalized care to diagnose and treat people with pancreatic cancer. Our team of specialists is at the forefront of groundbreaking research, studying promising new treatments and pioneering methods for detecting pancreatic cancer earlier, when it’s most treatable.

Our experts create an individualized treatment plan for you, drawing on our expertise in endoscopic and surgical treatments as well as medical therapies. Learn more about our comprehensive care for pancreatic cancer at Perlmutter Cancer Center’s Pancreatic Cancer Center.

Clinical Trials and Research Studies

Phase 1

A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)

Learn More

Phase 5

A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma

Learn More

Phase 5

A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS

Learn More

Phase 1

A Phase 1b Study to Determine the Safety and Tolerability and Confirm the Dose of Canakinumab and Spartalizumab in Combination With Nab-paclitaxel and Gemcitabine for Patients with Metastatic Pancreatic Cancer

Learn More